Literature DB >> 23329226

Refractory gastroesophageal reflux disease.

Joaquim Prado P Moraes-Filho1.   

Abstract

CONTEXT: Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Its pathophysiology, diagnosis and treatment have frequently been analyzed but it is interesting to review some aspects of the GERD refractory patients to the proton pump inhibitors treatment. The treatment encompasses behavioral measures and pharmacological therapy. The majority of the patients respond well to proton pump inhibitors treatment but 20%-42% of them may not do so well. Patients who are unresponsible to 4-8 weeks' treatment with proton pump inhibitors (omeprazole, pantoprazole, rabeprazole, lansoprazole, esomeprazole, pantoprazole-Mg) might have so-called refractory GERD.
RESULTS: In some cases the patients are not real refractory because either they do not have GERD or the disease was not correctly treated, but the term refractory is still employed. Although debatable, the Brazilian GERD Consensus based upon evidences recommends as first step in the diagnosis, the upper digestive endoscopy to exclude the diagnosis of peptic ulcer and cancer and in some cases identify the presence of esophageal mucosa erosions.
CONCLUSIONS: The main causes of the so-called refractory GERD are: (1) functional heartburn; (2) low levels of adherence to proton pump inhibitors treatment; (3) inadequate proton pump inhibitors dosage; (4) wrong diagnosis; (5) co-morbidities and pill-induced esophagitis; (6) genotypic differences; (7) nonacid gastroesophageal reflux; (8) autoimmune skin diseases; (9) eosinophilic esophagitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23329226     DOI: 10.1590/s0004-28032012000400012

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  8 in total

Review 1.  Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis.

Authors:  Xiaoquan Huang; Shiyao Chen; Hetong Zhao; Xiaoqing Zeng; Jingjing Lian; Yujen Tseng; Jie Chen
Journal:  Surg Endosc       Date:  2016-08-05       Impact factor: 4.584

2.  Diagnosis and Anti-Reflux Therapy for GERD with Respiratory Symptoms: A Study Using Multichannel Intraluminal Impedance-pH Monitoring.

Authors:  Chao Zhang; Jimin Wu; Zhiwei Hu; Chao Yan; Xiang Gao; Weitao Liang; Diangang Liu; Fei Li; Zhonggao Wang
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

Review 3.  Clinical efficacy and safety of magnetic sphincter augmentation (MSA) and transoral incisionless fundoplication (TIF2) in refractory gastroesophageal reflux disease (GERD): a systematic review and meta-analysis.

Authors:  Saurabh Chandan; Babu P Mohan; Shahab R Khan; Lokesh K Jha; Amaninder J Dhaliwal; Mohammad Bilal; Muhammad Aziz; Andrew Canakis; Sumant Arora; Sarah Malik; Lena L Kassab; Suresh Ponnada; Ishfaq Bhat; Alexander T Hewlett; Neil Sharma; Stephanie McDonough; Douglas G Adler
Journal:  Endosc Int Open       Date:  2021-04-13

4.  Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study.

Authors:  Munyaradzi Chimukangara; Anahita D Jalilvand; W Scott Melvin; Kyle A Perry
Journal:  Surg Endosc       Date:  2018-08-27       Impact factor: 4.584

5.  Long-term outcomes of patients with refractory gastroesophageal reflux disease following a minimally invasive endoscopic procedure: a prospective observational study.

Authors:  Wei-Tao Liang; Zhong-Gao Wang; Feng Wang; Yue Yang; Zhi-Wei Hu; Jian-Jun Liu; Guang-Chang Zhu; Chao Zhang; Ji-Min Wu
Journal:  BMC Gastroenterol       Date:  2014-10-10       Impact factor: 3.067

Review 6.  Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2018-03-21

Review 7.  Management of gastroesophageal reflux disease in adults: a pharmacist's perspective.

Authors:  Brett MacFarlane
Journal:  Integr Pharm Res Pract       Date:  2018-06-05

8.  A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial.

Authors:  Kamran Bagheri Lankarani; Gholam Reza Sivandzadeh; Marziyeh Zare; Mohammadali Nejati; Ramin Niknam; Ali Reza Taghavi; Fardad Ejtehadi; Mahvash Alizade Naini; Maryam Moini; Mohammad Hossein Anbardar; Payam Peymani
Journal:  Acta Biomed       Date:  2020-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.